Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

FK506 in solid organ transplantation

Fung, JJ and Starzl, TE (1995) FK506 in solid organ transplantation. Therapeutic Drug Monitoring, 17 (6). 592 - 595. ISSN 0163-4356

[img]
Preview
PDF
Accepted Version
Available under License : See the attached license file.

Download (682kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

FK506 (Prograf) is a new immunosuppressive agent, recently approved for use in solid organ transplants. The first use of FK506 was for the indication of refractory liver allograft rejection. This revealed a marked ability to reverse ongoing rejection, even in cases where chronic changes were observed. Between 50 and 70% of patients converted to FK506 had shown improvement. In long-term follow-up of patients with chronic rejection, 75% of patients were still alive at 3 years following FK506 conversion, and 65% of liver allografts were still functioning. FK506 has been compared to cyclosporine in primary liver transplantation. In the three randomized trials, freedom from rejection was statistically greater in the FK506-treated group, as compared to the cyclosporine-treated group. By intent-to-treat analysis, the patient and graft survival in the FK506 group was the same or better than the cyclosporine group. The good results in the cyclosporine limb was due, in part, to the ability of FK506 to treat rejection in the cyclosporine group. Freedom from steroid use, and the lower incidence of hypertension, were prominent features of FK506 patients. FK506 has been used for rescue of rejecting kidney allografts, with results similar to the liver transplant trials. When used as primary immunosuppression, FK506 was shown to be effective, as measured by graft survival. FK506-based immunosuppression has also been used in primary heart transplantation, as well as for primary adult pulmonary transplantation. Results from these small series of patients are equally encouraging. The results of these studies suggest that FK506 is effective for solid organ transplantation. Both FK506 and cyclosporine administration have been associated with side effects, many of which are similar, and some of which are peculiar to a given organ transplant. © 1995 Lippincott-Raven Publishers, Philadelphia.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Fung, JJ
Starzl, TEtes11@pitt.eduTES11
Centers: Other Centers, Institutes, or Units > Thomas E. Starzl Transplantation Institute
Date: 1 January 1995
Date Type: Publication
Journal or Publication Title: Therapeutic Drug Monitoring
Volume: 17
Number: 6
Page Range: 592 - 595
Institution: University of Pittsburgh
Refereed: Yes
ISSN: 0163-4356
Other ID: uls-drl:31735062121664, Starzl CV No. 1816
Date Deposited: 08 Apr 2010 17:31
Last Modified: 30 Oct 2017 23:56
URI: http://d-scholarship.pitt.edu/id/eprint/5202

Metrics

Monthly Views for the past 3 years

Plum Analytics


Actions (login required)

View Item View Item